WCLC 2017: Phase Ib/II savolitinib plus Tagrisso® in MET-driven NSCLC

OA 09.03 – TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI

Myung-Ju Ahn, Ji-Youn Han, Lecia V Sequist, Byoung Chul Cho, J.S. Lee, Sang-We Kim, W. Su, C. Tsai, James Chih-Hsin Yang, Helena Yu, L. Horn, K. Lee, V. Haddad, M.M. Frigault, G. Ahmed, L. Yang, D. Ghiorghiu, Geoffrey R. Oxnard

Venue: IASLC 18th World Conference on Lung Cancer
Session: OA 09 – EGFR TKI Resistance (ID 663)
Presenter: Myung-Ju Ahn
Date: Tuesday, October 17, 2017

For a summary of the data presented, please see the company overview presentation.